期刊论文详细信息
Frontiers in Endocrinology
Evaluating the TUITEK® patient support program in supporting caregivers of children diagnosed with growth hormone deficiency in Argentina
Endocrinology
Selina Graham1  Jonathan Reston1  Amrit Jheeta1  Ekaterina Koledova2  Aria Reza Assefi3  Matías Debicki3  Judit Gonzalez3  María Lourdes Crespo3 
[1] Atlantis Healthcare, London, United Kingdom;Global Medical Affairs Cardiometabolic and Endocrinology, Merck KGaA, Darmstadt, Germany;Medical Department, Merck S.A. (an affiliate of Merck KGaA, Darmstadt, Germany), Buenos Aires, Argentina;
关键词: adherence;    caregiver;    electronic injection device;    growth disorders;    pediatric;    patient support program;    recombinant human growth hormone treatment;    short stature;   
DOI  :  10.3389/fendo.2023.1129385
 received in 2022-12-21, accepted in 2023-03-28,  发布年份 2023
来源: Frontiers
PDF
【 摘 要 】

IntroductionThe appropriate use of recombinant human growth hormone (r-hGH) treatment provides an opportunity to improve growth outcomes among pediatric patients with growth hormone deficiency (GHD). However, a major challenge in clinical practice is to adequately recognize and address factors that negatively affect treatment adherence. TUITEK® patient support program (PSP) was designed to help caregivers of children diagnosed with GHD to personalize the care pathway, improve adherence, and achieve better outcomes. Effectiveness of TUITEK® PSP has been demonstrated previously in a smaller sample (n = 31) in Taiwanese population. Here, we present the results from Argentina.MethodsTUITEK® PSP was piloted among 76 caregivers of children with GHD administering r-hGH using easypod™ (Merck KGaA, Darmstadt, Germany) auto-injector device in Argentina. Based on TUITEK® personalization questionnaire, caregivers were assigned to high- and low-risk groups across four categories that may influence adherence, including disease and treatment coherence (DTC), self-administration (SA), treatment-related anxiety (TRA), and emotional burden (EB). The caregivers who were included in atleast one high-risk group had the provision of telephone calls with a nurse practitioner every 2 weeks for 3 months. The Wilcoxon signed-rank test was employed to assess changes in questionnaire-based scoring patterns between baseline and follow-up evaluations.ResultsStatistically significant changes (p < 0.05) in questionnaire scores between baseline and follow-up evaluations were observed across the four categories. The mean/median DTC (n = 11) and SA (n = 23) scores changed from 2.45/3 and 2.17/2, respectively, to 4/4, with all the caregivers moving to low-risk group following program completion (100%) for both categories. The mean/median TRA score (n = 40) changed from 3.58/3 to 2.5/2 and 67.5% of patients (27/40) moved to low-risk group. The mean/median EB score (n = 32) changed from 3.69/3 to 3.13/3 however, none of the caregivers moved to low-risk group (0%).ConclusionTUITEK® PSP is a simple, practical, and time-efficient interventional tool that can be used to address key adherence-related issues among caregivers of children with GHD and provide personalized adherence support. Our findings demonstrate that TUITEK® PSP has the potential to improve treatment adherence and self-management, thereby improving growth outcomes in Argentina.

【 授权许可】

Unknown   
Copyright © 2023 Assefi, Graham, Crespo, Debicki, Reston, Gonzalez, Jheeta and Koledova

【 预 览 】
附件列表
Files Size Format View
RO202310107086646ZK.pdf 792KB PDF download
  文献评价指标  
  下载次数:10次 浏览次数:1次